top of page

Last Week in Antitrust Litigation (#086)

4 days ago
6 min read

Week of November 9, 2026


Top Takeaways


  1. Customer Switching Can Undercut Monopoly-Power Claims: The Tekion court granted CDK summary judgment, citing its declining, sub-50% market share and Tekion’s success winning major customers despite disputed entry barriers. The ruling highlights why evidence of actual competitive gains matters when assessing whether alleged data-access restrictions confer monopoly power.

  2. Sales Between Rivals Do Not Necessarily Avoid Per Se Treatment: The Fragrance court allowed price-fixing claims to proceed under the per se rule because inter-defendant sales allegedly helped monitor and enforce the horizontal agreement. The ruling underscores that commercial transactions between competitors do not automatically transform alleged pricing coordination into a vertical restraint subject to the rule of reason.

  3. Physician-Network Consolidation Draws Buyer- and Seller-Side Claims: The Lee complaint alleges that a rival-network acquisition, physician exclusivity, and patient transfers enabled defendants to suppress physician compensation while demanding higher payments from health plans. The case highlights why healthcare acquisition reviews should examine physician mobility and patient-transfer practices alongside bargaining power with health plans.


New Cases Filed


Lee v. Seoul Med. Grp. (C.D. Cal. Nov. 12, 2026): Two doctors filed a putative class action against Seoul Medical, Swan Practice, SMG Aggregator, Ascend Capital, Ascend SMG Aggregator, and Advanced Medical alleging that defendants acquired SMG’s closest rival, Korean-American Medical Group (“KMG”), and used physician exclusivity and patient block-transfer practices to monopolize and attempt to monopolize the market for Korean-Senior MA Network Services and monopsonize the related market for the professional services of Korean-speaking physicians serving Medicare Advantage patients in Los Angeles and Orange Counties in violation of, among others, Section 7 of the Clayton Act and Section 2 of the Sherman Act. The complaint alleges that after acquiring SMG and then KAMG, defendants combined two of the leading Korean-serving physician networks, demanded exclusivity from Korean-speaking physicians, reassigned departing physicians’ patients to other SMG doctors so that the associated capitation remained with the enterprise, and reduced physician compensation while demanding higher payments from health plans. According to the complaint, the conduct eliminated head-to-head competition between SMG and KAMG, increased concentration, foreclosed rival IPAs from the physicians and attributed members needed to compete, suppressed physician compensation and mobility, and reduced Korean-American Medicare Advantage seniors’ choice, quality, service, and continuity of care.

 

The follow-on cases that were filed are:


  • City of Jacksonville v. REV Grp. (E.D. Wis. Nov. 10, 2026) (alleging defendants conspired to inflate the price of fire trucks like in City of La Crosse v. Oshkosh Corp. (E.D. Wis. Aug. 20, 2025))

  • Compass, Inc. v. Combined L.A./Westside MLS, Inc. (C.D. Cal. Nov. 12, 2026) (alleging defendant engaged in anticompetitive conduct that precluded sellers from marketing their properties outside of the MLS like in Compass, Inc. v. Nw. Multiple Listing Serv. (W.D. Wash. Apr. 25, 2025)); Compass, Inc. v. BridgeMLS, Inc. (N.D. Cal. Nov. 12, 2026) (same); Compass, Inc. v. Bay E. Ass'n of REALTORS (N.D. Cal. Nov. 12, 2026) (same); Compass, Inc. v. Hou. Realtors Info. Serv., Inc. (S.D. Tex. Nov. 12, 2026) (same); Compass, Inc. v. Contra Costa Ass'n of REALTORS (N.D. Cal. Nov. 12, 2026) (same); Compass, Inc. v. MLSListings Inc. (N.D. Cal. Nov. 12, 2026) (same); Compass, Inc. v. San Diego Multiple Listing Serv., Inc. (S.D. Cal. Nov. 12, 2026) (same); Compass, Inc. v. Metrolist, Inc. (D. Colo. Nov. 12, 2026) (same); Compass, Inc. v. My Fl. Reg'l MLS, Inc. (M.D. Fl. Nov. 12, 2026) (same); Compass, Inc. v. Reg'l Multiple Listing Serv. of Minn., Inc. (D. Minn. Nov. 12, 2026) (same); Compass, Inc. v. Triangle MLS, Inc. (E.D.N.C. Nov. 12, 2026) (same); Compass, Inc. v. N. Carolina Reg'l MLS, LLC (E.D.N.C. Nov. 12, 2026) (same); Compass, Inc. v. Carolina Multiple Listing Servs., Inc. (W.D.N.C. Nov. 12, 2026) (same); Compass, Inc. v. OneKey MLS LLC (E.D.N.Y. Nov. 12, 2026) (same)


Dispositive Orders and TROs


In re Fragrance Direct Purchaser Antitrust Litig. (D.N.J. Nov. 9, 2026): In this class action claiming that fragrance manufacturers conspired to fix prices and restrict competition, the court denied defendants’ motion for judgment on the pleadings. The court reasoned that the alleged restraint was properly treated as a horizontal price-fixing conspiracy subject to the per se rule because plaintiffs alleged that defendants, as competitors operating at the same level of the fragrance supply chain, agreed to restrict price competition and used inter-defendant sales to enforce and monitor that agreement, while the existence of those sales did not transform the alleged conspiracy into a hybrid horizontal-and-vertical arrangement subject to the rule of reason. The court therefore held that plaintiffs plausibly stated their Sherman Act claim under the per se framework and, because the state antitrust claims were analyzed under the same standards, allowed those claims to proceed as well.

 

Tekion Corp. v. CDK Glob., LLC (N.D. Cal. Nov. 10, 2026): In this case alleging CDK used its control over dealer data to prevent migrations to rival dealership management systems (“DMS”), the court granted CDK’s motion for summary judgment on both antitrust claims. The court reasoned that (a) Tekion’s operative complaint alleged only the nationwide franchise-DMS market and could not proceed on a later-added enterprise-dealer submarket theory, (b) no reasonable jury could find that CDK possessed monopoly power because its market share during the relevant 2023–2024 period was below 50% whether measured by dealership rooftops or revenue, its share was declining, and Tekion itself was rapidly expanding and winning major CDK customers, and (c) although factual disputes existed over whether customer switching costs and OEM-certification requirements constituted entry barriers, the record did not support network effects or capital costs as significant barriers and, taken as a whole, did not show CDK had the power to control output or exclude competition or was dangerously close to acquiring such power. The court also denied Tekion’s Rule 56(d) request for additional discovery, finding that Tekion had not diligently pursued the revenue data it claimed to need or shown that further discovery would alter the result, and excluded Tekion’s expert’s revenue-share estimate as unreliable because it depended on Bain and McKinsey figures derived from undisclosed methodologies.

 

Class Actions and Other Settlements


Pro Slab, Inc. v. Argos USA, LLC (D.S.C. Nov. 5, 2026): In this class action alleging price-fixing of Ready-Mix Concrete, the court granted final approval of a settlement with Argos USA and Argos Ready Mix. The court confirmed certification of a settlement class of persons and entities that directly purchased ready-mix concrete from specified defendants’ plants from January 1, 2010 through July 31, 2016, finding the settlement fair, reasonable, and adequate and the notice program sufficient under Rule 23 and due process. The court approved the settlement releases, dismissed the claims against Argos with prejudice, retained jurisdiction over administration and distribution of the settlement fund, and directed entry of final judgment under Rule 54(b).

 

State of Connecticut v. Aurobindo Pharma USA, Inc. (D. Conn. Nov. 5, 2026): In this case alleging price-fixing, market allocation, and bid rigging among generic drug manufacturers, the court granted final approval of the plaintiff states’ settlement with Glenmark Pharmaceuticals. The court found the settlement fair, reasonable, and adequate and the product of arm’s-length, informed, and non-collusive negotiations, and approved the notice provided to eligible consumers and corporate entities. The court approved allocation of 70% of the settlement funds, after amounts reserved for eligible corporate entities, to restitution and 30% to notice, administration, and litigation costs, including approximately $13.26 million for eligible consumers and $7.28 million for state entities. The court dismissed the claims against Glenmark with prejudice, retained jurisdiction over administration and enforcement of the settlement, and made the approval order final and immediately appealable as to Glenmark.


***      ***      ***


If you have any antirust questions or would like more information about any of these matters, please contact one of the following authors:



 

This newsletter has been prepared by Kressin Powers LLC for educational and informational purposes only regarding selected recent legal developments and does not constitute advertising or solicitation. No legal or business decision should be based on its content. Neither this publication nor the lawyers who authored it are rendering legal or other professional advice or opinions on specific facts or matters, nor does the distribution of this publication to any person constitute the establishment of an attorney-client relationship. Those seeking legal advice should contact a member of the Firm or legal counsel licensed in their jurisdiction. The invitation to contact is not a solicitation for legal work under the laws of any jurisdiction in which Kressin Powers LLC lawyers are not authorized to practice. Confidential information should not be sent to Kressin Powers LLC without first communicating directly with a member of the Firm about establishing an attorney-client relationship.


Recent Posts

See All
Last Week in Antitrust Litigation (#085)

Week of November 2, 2026 Top Takeaways Reverse-Payment Risk Turns on the Full Settlement Package: The Niaspan court denied defendants’ summary judgment motions, finding that a no-authorized-generic co

 
 
 
Last Week in Antitrust Litigation (#084)

Week of October 26, 2026 Top Takeaways Loyalty Programs Face Scrutiny Beyond Discounts: The Syngenta court denied summary judgment, analyzing the challenged program as exclusive dealing rather than ap

 
 
 
Last Week in Antitrust Litigation (#083)

Week of October 19, 2026 Top Takeaways Keurig’s Contract Restrictions Remain a Trial Risk: The court allowed key exclusive-dealing and tying claims involving supplier, distributor, and roaster agreeme

 
 
 

Comments


  • LinkedIn
  • X

© 2025 by Kressin Powers LLC.

bottom of page